<DOC>
	<DOCNO>NCT00527514</DOCNO>
	<brief_summary>This study conduct assess efficacy safety amlodipine/olmesartan treatment regimen stage 1 stage 2 hypertensive subject .</brief_summary>
	<brief_title>Blood Pressure Lowering Ability Safety Olmesartan Amlodipine Based Treatment Regimen Patients With Stage I Stage II Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Males female great equal 18 year age Patients mean seat systolic blood pressure ( MSSBP ) great equal 140 mm Hg le equal 199 mm Hg mean seat diastolic blood pressure ( MSDBP ) great equal 90 mm Hg le equal 109 mm Hg , follow period take placebo Patients mean daytime ( 8AM4PM ) systolic blood pressure great equal 135 mm Hg le equal 199 mm Hg mean daytime diastolic blood pressure less equal 109 mm Hg measure ambulatory blood pressure monitoring device ( ABPM ) , period take placebo If female , must negative serum pregnancy test screen either postmenopausal ( great equal 1 year ) , hysterectomy tubal ligation least 6 month consent childbearing potential , must practice approve measure birth control throughout study History stroke transient ischemic attack ( TIA ) within last one year History myocardial infarction , coronary angioplasty , coronary artery bypass graft , heart failure within past 6 month Patients secondary hypertension etiology , renal disease , pheochromocytoma , Cushing 's syndrome Type I diabetes . Patients Type II diabetes stable treatment , fast glucose &lt; 160 mg/dl may enroll Patients hemodynamically significant cardiac valvular disease Patients clinically significant cardiac conduction defect , include second third degree AV block , leave bundle branch block , sick sinus syndrome , atrial fibrillation , atrial flutter , accessory bypass tract , arrhythmia require medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Angiotensin Receptor Blocker</keyword>
	<keyword>Calcium Channel Blocker</keyword>
	<keyword>Stage I II Hypertension</keyword>
</DOC>